Introduction
Breast malignancy presents a noteworthy worldwide health issue, exhibiting fluctuating occurrence and fatality statistics across diverse locales. Although mammography (MAM) stands as the primary method for breast cancer screening in affluent nations, its accessibility and practicality face restrictions in low- and middle-income nations (LMICs) due to resource limitations. Hence, there is a keen interest in investigating the use of ultrasound (US) as a substitute or supplementary screening approach, particularly in areas with limited access to MAM.
Condition and Screening
Breast cancer is an aggressive tumor stemming from breast cells. From an epidemiological perspective, it ranks as the most prevalent cancer among women globally and a primary contributor to cancer-induced fatalities in women (Dan et al., 2023). This ailment poses a substantial public health challenge, underscoring the importance of timely screening to enhance prognosis and survival.
Epidemiology of Condition
In the context of the United States, breast cancer epidemiology encompasses three key statistical measures: incidence, mortality, and prevalence. According to recent findings, the incidence rate stands at approximately 126.0 new cases per 100,000 women annually (Richman et al., 2023). Correspondingly, the mortality rate is estimated at 20.1 deaths per 100,000 women per year (Richman et al., 2023).
Patterns suggest a consistent or slightly rising incidence rate alongside a declining mortality rate, largely due to advances in early detection and treatment. Additionally, there are disparities in breast cancer occurrence and mortality rates across demographic categories like race, gender, and age, with higher rates noted among older non-Hispanic white females and those with particular genetic predispositions.
Methodology
The United States Preventive Services Task Force (USPSTF) adopts a meticulous methodology to develop breast cancer screening guidelines, relying on evidence-based recommendations. This process entails a comprehensive review of available evidence, rigorous assessment of study quality, and careful evaluation of screening benefits versus potential harms (Tsai et al., 2023). With a focus on women aged 50 to 74, particular attention is given to risk factors such as family history and previous breast lesions (Richman et al., 2023).
Statistical reasoning serves as a cornerstone in substantiating the screening guidelines for this demographic. Research consistently indicates a notably heightened susceptibility to breast cancer among individuals with familial ties to the ailment. For example, those with a close familial connection diagnosed with breast cancer face approximately double the risk of contracting the disease compared to those lacking such a familial background (Richman et al., 2023). Correspondingly, females with a past occurrence of non-malignant breast abnormalities exhibit an increased likelihood of future breast cancer onset, emphasizing the necessity of focused screening initiatives.
Guideline
The USPSTF suggests biennial screening mammography for women aged 50 to 74 years. However, for women aged 40 to 49 years, the decision on whether to start regular biennial screening mammography should be tailored to the individual’s values, preferences, and health background (Dan et al., 2023). The latest guidelines underscore the importance of a joint decision-making process between individuals and medical professionals when assessing the suitability of mammogram screening for certain age groups (Dan et al., 2023). This method combines the patient’s personal values and choices with medical data to ensure that screening decisions are tailored to the individual’s unique situation, balancing the benefits of screening with potential risks.
Critical Analysis and Literature Review
A critical analysis of the USPSTF guidelines through a literature review reveals support for the recommendations and may also include more recent studies offering alternative views. For instance, the study by Tsai et al. (2023) suggests the importance of chronic disease management in cancer survivorship care. It indicates that multi-morbidities are positively associated with colorectal cancer screening among breast cancer survivors.
Richman et al. aimed to gauge the extent of overdiagnosis linked with mammography screening in older women. Their retrospective cohort analysis contrasted breast cancer occurrence between women who persisted with screening and those who did not. The findings indicated a rise in breast cancer occurrence linked with ongoing screening, indicating a notable overdiagnosis risk (Richman et al., 2023). Nevertheless, there were no significant declines in breast cancer-related mortality associated with screening. These outcomes underscore the need to weigh the potential harms of overdiagnosis against the benefits of screening.
Chen et al. addressed the racial disparities in mortality by proposing race and ethnicity–adapted starting ages for breast cancer screening. The research examined breast cancer mortality statistics and proposed that Black women commence screening 8 years earlier, starting at age 42. In contrast, White, American Indian/Alaska Native, Hispanic, and Asian or Pacific Islander women might commence later than the typical recommendation of 50 years (Chen et al., 2023). This alternative strategy seeks to tackle mortality resulting from early-onset breast cancer and improve the fairness of screening initiatives.
Dan et al. reviewed the role of ultrasound (US) as an alternative screening method for breast cancer in low-resource settings. The review highlighted that the US is particularly beneficial for younger women and those with dense breasts, where mammography may be less effective (Dan et al., 2023). The study discussed the advancements in US technology, including computer-aided detection and deep learning, which could improve screening efficacy (Dan et al., 2023). The authors recommend implementing resource-appropriate strategies for breast cancer screening in LMICs, where ultrasound could be a cost-effective primary screening tool.
Conclusion
In summary, knowledge of epidemiology and preventive screening guidelines is critical for master ‘s-prepared nurses in clinical practice. For breast cancer, understanding the condition’s epidemiology, utilizing USPSTF recommendations, and critically analyzing guideline support and alternative views are essential for ordering appropriate preventive screenings for patients.
References
Chen, T., Kharazmi, E., & Fallah, M. (2023). Race and Ethnicity–Adjusted Age Recommendation for Initiating Breast Cancer Screening. JAMA Network Open, 6(4).
Dan, Q., Zheng, T., Liu, L., Sun, D., & Chen, Y. (2023). Ultrasound for Breast Cancer Screening in Resource-Limited Settings: Current Practice and Future Directions. Cancers, 15(7).
Richman, I. B., Long, J. B., Soulos, P. R., Shi Yi Wang, & Gross, C. P. (2023). Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals of Internal Medicine, 176(9), 1172–1180.
Tsai, M.-H., Grunert, C., Vo, J. B., Moore, J. X., & Guha, A. (2023). Presence of Multi-Morbidities and Colorectal Cancer Screening Utilization among Breast Cancer Survivors. Cancers, 15(7).